Young Whang, MD, PhD

Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer

Press release of the trial of Pluvicto in metastatic hormone-sensitive prostate cancer (PSMAddition) meeting the primary endpoint.
www.novartis.com/news/media-r...

The story behind the NIH indirect cap.
www.msn.com/en-us/news/p...

GLP-1 for Complex Cases: Breakthrough Therapies in Care Unlock the potential of GLP-1 therapies! Join experts to explore cutting-edge strategies for managing cardiovascular & endocrine cases. Enhance outcomes for complex patients with actionable insights.

Excellent discussion on the current realities of using GLP-1 RAs in complex cases and in underserved communities in this Medscape Masters Series. Honored to participate as a guest with Drs. Jamie Almandoz, Ambarish Pandey & Tamaan K. Osbourne - Roberts www.medscape.com/viewarticle/...

‘Never seen anything like this’: Trump’s team halts NIH meetings and travel In an unprecedented move, research-grant reviews have been suspended indefinitely at the world’s largest public funder of biomedical research.

Unless this is reversed quickly, I'm concerned for the long term damage to biomedical research in the US.

www.nature.com/articles/d41...